A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result

Prostate Cancer and Prostatic Diseases

Volumn 18, Issue 4, 2015, Pages 370-375

  Donovan, M J ^a,b   Noerholm, M ^b   Bentink, S ^b   Belzer, S ^b   Skog, J ^b   O'Neill, V ^b   Cochran, J S ^c   Brown, G A ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Exosome Diagnostics   (United States)

^c Urology Clinic of North Texas   (Mexico)

^d Delaware Valley Urology LLC Voorhees   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERG EXOSOMAL RNA; KALLIKREIN; KALLIKREIN RELATED PEPTIDASE 3; ONCOPROTEIN; PROSTATE CANCER ANTIGEN 3; RNA; UNCLASSIFIED DRUG; ERG PROTEIN, HUMAN; PROSTATE CANCER ANTIGEN 3, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CAUCASIAN; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL RECTAL EXAMINATION; ELECTRON MICROSCOPY; EXOSOME; FEASIBILITY STUDY; GLEASON SCORE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RACE DIFFERENCE; RECEIVER OPERATING CHARACTERISTIC; URINALYSIS; BIOPSY; GENETICS; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; REPRODUCIBILITY; URINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; BIOPSY; EXOSOMES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RNA; ROC CURVE; TRANS-ACTIVATORS;

EID: 84947034977     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2015.40     Document Type: Article

References (37)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA J Clin. 2014; 64: 9-29.
2. Bjurlin MA, Wysock JS, Taneja SS. Optimization of prostate biopsy: review of technique and complications. Urol Clin North Am. 2014; 41: 299-313.
3. Lundstrom KJ, Drevin L, Carlsson S, Garmo H, Loeb S, Stattin P, et al. Nationwide population based study of infections after transrectal ultrasound guided prostate biopsy. J Urol. 2014; 192: 1116-1122.
4. Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol. 2010; 183: 963-968.
5. Bruyere F, Malavaud S, Bertrand P, De cock A, Cariou G, Doublet JD, et al. Prosbiotate: a multicenter, prospective analysis of infectious complications after prostate biopsy. J Urol. 2014; 193: 145-150.
6. Abouassaly R, Thompson IM Jr, Platz EA, Klein EA. Epidemiology, etiology, and prevention of prostate cancer. In: McDougal WS, Wein A, Kavoussi L, Novick AC, Partin AW, Peters CA et al (eds). Campbell-Walsh Urology, 10th edn. Elsevier Saunders: Philadelphia, PA, USA, 2012.
7. Berman DM, Epstein JI. When is prostate cancer really cancer?. Urol Clin North Am. 2014; 41: 339-346.
8. Klotz L. Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Curr Treat Opt Oncol. 2006; 7: 355-362.
9. Getzenberg RH, Partin AW. Prostate cancer tumor markers. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (eds). Campbell-Walsh Urology, 10th edn. Elsevier Saunders: Philadelphia, PA, USA, 2012.
10. Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013; 64: 876-892.
11. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the european randomised study of screening for prostate cancer (ERSPC) at 13 years of follow-up. Lancet. 2014; 384: 2027-2035.
12. Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014; 370: 932-942.
13. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012; 367: 203-213.
14. van der Vos KE, Balaj L, Skog J, Breakefield XO. Brain tumor microvesicles: insights into intercellular communication in the nervous system. Cell Mol Neurobiol. 2011; 31: 949-959.
15. Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield XO, et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer. 2009; 100: 1603-1607.
16. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10: 1470-1476.
17. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9: 654-659.
18. Miranda KC, Bond DT, McKee M, Skog J, Paunescu TG, Da Silva N, et al. Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease. Kidney Int. 2010; 78: 191-199.
19. Miranda KC, Bond DT, Levin JZ, Adiconis X, Sivachenko A, Russ C. Massively parallel sequencing of human urinary exosome/microvesicle RNA reveals a predominance of non-coding RNA. PLoS One. 2014; 9: e96094.
20. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Nati Cancer Inst. 2006; 98: 529-534.
21. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level o or=4.0 ng per milliliter. N Engl J Med. 2004; 350: 2239-2246.
22. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003; 44: 8-15; discussion -6.
23. St John J, Powell K, Conley-Lacomb MK, Chinni SR. TMPRSS2-ERG fusion gene expression in prostate tumor cells and its clinical and biological significance in prostate cancer progression. J Cancer Sci Ther. 2012; 4: 94-101.
24. Gittelman MC, Hertzman B, Bailen J, Williams T, Koziol I, Henderson RJ, et al. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol. 2013; 190: 64-69.
25. Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, et al A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 2008; 68: 645-649.
26. Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, et al. Noninvasive detection of TMPRSS2: ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia. 2006; 8: 885-888.
27. Leyten GH, Hessels D, Jannink SA, Smit FP, De Jong H, Cornel EB, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2014; 65: 534-542.
28. Rice KR, Chen Y, Ali A, Whitman EJ, Blase A, Ibrahim M, et al. Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer. Clin Cancer Res. 2010; 16: 1572-1576.
29. Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, et al. Combining urinary detection of TMPRSS2: ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol. 2013; 31: 566-571.
30. Dijkstra WS, Birker IL, Smit FP, Leyten GH, De Reijke TM, van Oort IM, et al. Prostate cancer biomarker profiles in urinary sediments and exosomes. J Urol. 2014; 191: 1132-1138.
31. Cheng XH, Black M, Ustiyan V, Le T, Fulford L, Sridharan A, et al. SPDEF inhibits prostate carcinogenesis by disrupting a positive feedback loop in regulation of the Foxm1 oncogene. PLoS Genet. 2014; 10: e1004656.
32. Haller AC, Tan W, Payne-Ondracek R, Underwood W, Tian L, Morrison C, et al. High SPDEF may identify patients who will have a prolonged response to androgen deprivation therapy. Prostate. 2014; 74: 509-519.
33. Oettgen P, Finger E, Sun Z, Akbarali Y, Thamrongsak U, Boltax J, et al. PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J Biol Chem. 2000; 275: 1216-1225.
34. Hagen RM, Adamo P, Karamat S, Oxley J, Aning JJ, Gillatt D, et al. Quantitative analysis of ERG expression and its splice isoforms in formalinfixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence. Am J Clin Pathol. 2014; 142: 533-540.
35. Svensson MA, Perner S, Ohlson AL, Day JR, Groskopf J, Kirsten R, et al A comparative study of ERG status assessment on DNA, mRNA, and protein levels using unique samples from a Swedish biopsy cohort. Appl Immunohistochem Mol Morphol. 2014; 22: 136-141.
36. He J, Schepmoes AA, Shi T, Wu C, Fillmore TL, Gao Y, et al. Analytical platform evaluation for quantification of ERG in prostate cancer using proteins and mRNA detection methods. J Transl Med. 2015; 54: 1-14.
37. Hansen J, Rink M, Bianchi M, Kluth LA, Tian Z, Ahyai SA, et al. External validation of the updated Briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection. Prostate. 2013; 73: 211-218.